These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 36147599)

  • 1. Early Experience Implementing Long-Acting Injectable Cabotegravir/Rilpivirine for Human Immunodeficiency Virus-1 Treatment at a Ryan White-Funded Clinic in the US South.
    Collins LF; Corbin-Johnson D; Asrat M; Morton ZP; Dance K; Condra A; Jenkins K; Todd-Turner M; Sumitani J; Smith BL; Armstrong WS; Colasanti JA
    Open Forum Infect Dis; 2022 Sep; 9(9):ofac455. PubMed ID: 36147599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early Implementation and Outcomes Among People with HIV Who Accessed Long-Acting Injectable Cabotegravir/Rilpivirine at Two Ryan White Clinics in the U.S. South.
    Haser GC; Balter L; Gurley S; Thomas M; Murphy T; Sumitani J; Leue EP; Hollman A; Karneh M; Wray L; Washington M; Corbin-Johnson D; Condra A; Niles-Carnes L; Smith BL; Armstrong WS; Kalokhe AS; Colasanti JA; Collins LF
    AIDS Res Hum Retroviruses; 2024 Jul; ():. PubMed ID: 38959116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspectives Among Health Care Providers and People with HIV on the Implementation of Long-Acting Injectable Cabotegravir/Rilpivirine for Antiretroviral Therapy in Florida.
    Fisk-Hoffman RJ; Ranger SS; Gracy A; Gracy H; Manavalan P; Widmeyer M; Leeman RF; Cook RL; Canidate S
    AIDS Patient Care STDS; 2024 Jun; 38(6):275-285. PubMed ID: 38686517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient Attitudes Toward Self- or Partner-, Friend-, or Family-Administered Long-acting Injectable Antiretroviral Therapy: A Mixed-Methods Study Across 3 Urban Human Immunodeficiency Virus Clinics.
    Collins LF; Koester KA; McNulty MC; Montgomery ET; Johnson MO; Neilands TB; Dilworth SE; Sauceda JA; Dance K; Erguera X; Diaz Tsuzuki M; Gutierrez JI; Christopoulos KA; Colasanti JA
    Open Forum Infect Dis; 2024 Jun; 11(6):ofae265. PubMed ID: 38854389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving Adherence to the Target Window for Cabotegravir + Rilpivirine Long-Acting Injections Through the CHORUS™ App and Web Portal: A Cluster Randomized Trial.
    Wohlfeiler MB; Brunet L; Cochran Q; Fusco JS; Hsu RK; Fusco GP
    J Int Assoc Provid AIDS Care; 2024; 23():23259582241245223. PubMed ID: 38613372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirine.
    Patel P; Teichner P; Elliot E; Boffito M; Murray M; Polli JW; Baker M; Ford SL; Han K; Russu A; Crauwels H; D'Amico RD; Spreen WR; van Wyk J
    Ther Adv Infect Dis; 2023; 10():20499361231214626. PubMed ID: 38107552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Acting Injectable ART in Practice: A Mixed Methods Implementation Study Assessing the Feasibility of Using LAI ART in High Risk Populations and At Alternative Low Barrier Care Sites.
    Fletcher L; Burrowes S; Sabin LL; McCann N; Khan GK; Ruiz-Mercado G; Johnson S; Kimmel SD; Pierre C; Drainoni ML
    AIDS Patient Care STDS; 2024 May; 38(5):221-229. PubMed ID: 38656905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-center experience evaluating and initiating people with HIV on long-acting cabotegravir/rilpivirine.
    Hill LA; Abulhosn KK; Yin JF; Bamford LP
    AIDS; 2023 Mar; 37(4):605-609. PubMed ID: 36730069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).
    Chounta V; Overton ET; Mills A; Swindells S; Benn PD; Vanveggel S; van Solingen-Ristea R; Wang Y; Hudson KJ; Shaefer MS; Margolis DA; Smith KY; Spreen WR
    Patient; 2021 Nov; 14(6):849-862. PubMed ID: 34056699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementation of a Pharmacist-Led, Long-Acting, Injectable Cabotegravir/Rilpivirine Program for HIV-1 at Health System-Based Clinics in the New York Metropolitan Area.
    Nguyen NM; Kavanagh R; Gozar M; Cabral D; Goetz H; Cha A; McGowan JP; Pao ML
    AIDS Patient Care STDS; 2024 Mar; 38(3):115-122. PubMed ID: 38471090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying Implementation Determinants and Strategies for Long-Acting Injectable Cabotegravir-Rilpivirine in People With HIV Who Are Virally Unsuppressed.
    Hickey MD; Grochowski J; Mayorga-Munoz F; Oskarsson J; Imbert E; Spinelli M; Szumowski JD; Appa A; Koester K; Dauria EF; McNulty M; Colasanti J; Havlir DV; Gandhi M; Christopoulos KA
    J Acquir Immune Defic Syndr; 2024 Jul; 96(3):280-289. PubMed ID: 38534179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-acting injectable ART to advance health equity: a descriptive analysis of US clinic perspectives on barriers, needed support and programme goals for implementation from applications to the ALAI UP Project.
    Nguyen N; Lane B; Golub SA; Chastain C; Zucker J; King K; Terry M; Burdge J; Carnevale C; Muscarella A; Castor D; Kutner B; Meyers K
    J Int AIDS Soc; 2024 Jul; 27 Suppl 1(Suppl 1):e26282. PubMed ID: 38965977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Projected Benefits of Long-Acting Antiretroviral Therapy in Nonsuppressed People With Human Immunodeficiency Virus Experiencing Adherence Barriers.
    Chen W; Gandhi M; Sax PE; Neilan AM; Garland WH; Wilkin T; Cohen R; Ciaranello AL; Kulkarni SP; Eron J; Freedberg KA; Hyle EP
    Open Forum Infect Dis; 2023 Aug; 10(8):ofad390. PubMed ID: 37601728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicentre service evaluation of injectable cabotegravir and rilpivirine delivery and outcomes across 12 UK clinics (SHARE LAI-net).
    Ring K; Smuk M; Shongwe M; Okonta L; Mackie NE; Ayres S; Barber TJ; Akodu J; Ferro F; Chilton D; Hurn E; Halai B; Barchi W; Ali A; Darko S; White G; Clarke E; Clark F; Ali B; Arumainayagam J; Quinn G; Boffito M; Byrne R; Naous N; Leung S; Umaipalan A; Thornton B; Bayliss D; McLoughlin C; Foster J; Waters L; Orkin C
    HIV Med; 2024 Jun; ():. PubMed ID: 38858222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Realizing the promise of long-acting antiretroviral treatment strategies for individuals with HIV and adherence challenges: an illustrative case series.
    Kilcrease C; Yusuf H; Park J; Powell A; Rn LJ; Rn JO; Lmsw BD; Weld ED; Dooley KE; Arrington-Sanders R; Agwu AL
    AIDS Res Ther; 2022 Nov; 19(1):56. PubMed ID: 36435793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acceptability, Feasibility, and Appropriateness of Implementation of Long-acting Injectable Antiretrovirals: A National Survey of Ryan White Clinics in the United States.
    Tarfa A; Sayles H; Bares SH; Havens JP; Fadul N
    Open Forum Infect Dis; 2023 Jul; 10(7):ofad341. PubMed ID: 37520423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acceptability of Long-Acting Injectable Antiretroviral Therapy Among People with HIV Receiving Care at Three Ryan White Funded Clinics in the United States.
    Erguera XA; Koester KA; Diaz Tsuzuki M; Dance KV; Flores R; Kerman J; McNulty MC; Colasanti JA; Collins LF; Montgomery ET; Johnson MO; Sauceda JA; Christopoulos KA
    AIDS Behav; 2024 Jul; 28(7):2226-2238. PubMed ID: 38598026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First Demonstration Project of Long-Acting Injectable Antiretroviral Therapy for Persons With and Without Detectable Human Immunodeficiency Virus (HIV) Viremia in an Urban HIV Clinic.
    Christopoulos KA; Grochowski J; Mayorga-Munoz F; Hickey MD; Imbert E; Szumowski JD; Dilworth S; Oskarsson J; Shiels M; Havlir D; Gandhi M
    Clin Infect Dis; 2023 Feb; 76(3):e645-e651. PubMed ID: 35913500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency of genotypic factors possibly associated with cabotegravir/rilpivirine failure in antiretroviral treatment-naïve and -experienced HIV-1- infected population.
    Scheibe K; Urbańska A; Serwin K; Parczewski M
    Infect Genet Evol; 2022 Oct; 104():105358. PubMed ID: 36057423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implementation of long-acting cabotegravir and rilpivirine: primary results from the perspective of staff study participants in the Cabotegravir And Rilpivirine Implementation Study in European Locations.
    Gutner CA; Hocqueloux L; Jonsson-Oldenbüttel C; Vandekerckhove L; van Welzen BJ; Slama L; Crusells-Canales M; Sierra JO; DeMoor R; Scherzer J; Ait-Khaled M; Bontempo G; Gill M; Patel N; D'Amico R; Hove K; Baugh B; Barnes N; Hadi M; Low EL; Anand SB; Hamilton A; Garges HP; Czarnogorski M
    J Int AIDS Soc; 2024 Jul; 27(7):e26243. PubMed ID: 38978405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.